129 related articles for article (PubMed ID: 16210040)
1. Lessons from familial myeloproliferative disorders.
Skoda R; Prchal JT
Semin Hematol; 2005 Oct; 42(4):266-73. PubMed ID: 16210040
[TBL] [Abstract][Full Text] [Related]
2. Polycythemia and oxygen sensing.
Maran J; Prchal J
Pathol Biol (Paris); 2004 Jun; 52(5):280-4. PubMed ID: 15217714
[TBL] [Abstract][Full Text] [Related]
3. "Benign erythrocytosis" and other familial and congenital polycythemias.
Prchal JT; Sokol L
Eur J Haematol; 1996 Oct; 57(4):263-8. PubMed ID: 8982288
[TBL] [Abstract][Full Text] [Related]
4. Mutation in the negative regulatory element of the erythropoietin receptor gene in a case of sporadic primary polycythemia.
Sokol L; Prchal JF; D'Andrea A; Rado TA; Prchal JT
Exp Hematol; 1994 May; 22(5):447-53. PubMed ID: 8174675
[TBL] [Abstract][Full Text] [Related]
5. WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders.
Michiels JJ; De Raeve H; Hebeda K; Lam KH; Berneman Z; Schroyens W; Schwarz J
Leuk Res; 2007 Aug; 31(8):1031-8. PubMed ID: 17367853
[TBL] [Abstract][Full Text] [Related]
6. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
7. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
8. The erythropoietin receptor gene is not linked with the polycythemia phenotype in a family with autosomal dominant primary polycythemia.
Kralovics R; Sokol L; Broxson EH; Prchal JT
Proc Assoc Am Physicians; 1997 Nov; 109(6):580-5. PubMed ID: 9394420
[TBL] [Abstract][Full Text] [Related]
9. Influence of the assays of endogenous colony formation and serum erythropoietin on the diagnosis of polycythemia vera and essential thrombocythemia.
Mossuz P;
Semin Thromb Hemost; 2006 Apr; 32(3):246-50. PubMed ID: 16673278
[TBL] [Abstract][Full Text] [Related]
10. Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders.
Kralovics R; Skoda RC
Blood Rev; 2005 Jan; 19(1):1-13. PubMed ID: 15572213
[TBL] [Abstract][Full Text] [Related]
11. A der(18)t(9;18)(p13;p11) and a der(9;18)(p10;q10) in polycythemia vera associated with a hyperproliferative phenotype in transformation to postpolycythemic myelofibrosis.
Larsen TS; Hasselbalch HC; Pallisgaard N; Kerndrup GB
Cancer Genet Cytogenet; 2007 Jan; 172(2):107-12. PubMed ID: 17213018
[TBL] [Abstract][Full Text] [Related]
12. An inhibitor of Janus kinase 2 prevents polycythemia in mice.
Mathur A; Mo JR; Kraus M; O'Hare E; Sinclair P; Young J; Zhao S; Wang Y; Kopinja J; Qu X; Reilly J; Walker D; Xu L; Aleksandrowicz D; Marshall G; Scott ML; Kohl NE; Bachman E
Biochem Pharmacol; 2009 Aug; 78(4):382-9. PubMed ID: 19413997
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia.
Murphy S
Semin Hematol; 1999 Jan; 36(1 Suppl 2):9-13. PubMed ID: 9930551
[TBL] [Abstract][Full Text] [Related]
14. Prediction of clinical course in patients with idiopathic erythrocytosis by endogenous erythroid colony assay but not by serum erythropoietin levels.
Shih LY; Lee CT; Ou YC
Exp Hematol; 1997 Apr; 25(4):288-92. PubMed ID: 9131002
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of a one step sandwich enzymeimmunoassay for serum erythropoietin--serum erythropoietin values in polycythemia vera and related hematological disorders].
Sawabe Y; Iida S; Tabata Y; Yonemitsu H
Rinsho Byori; 1993 Jan; 41(1):75-82. PubMed ID: 8355412
[TBL] [Abstract][Full Text] [Related]
16. In vitro erythropoiesis in polycythemia vera and other myeloproliferative disorders.
Weinberg RS
Semin Hematol; 1997 Jan; 34(1):64-9. PubMed ID: 9025164
[TBL] [Abstract][Full Text] [Related]
17. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
18. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin.
Liu E; Jelinek J; Pastore YD; Guan Y; Prchal JF; Prchal JT
Blood; 2003 Apr; 101(8):3294-301. PubMed ID: 12515724
[TBL] [Abstract][Full Text] [Related]
19. The role of beta-catenin in chronic myeloproliferative disorders.
Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis.
Mossuz P; Girodon F; Donnard M; Latger-Cannard V; Dobo I; Boiret N; Lecron JC; Binquet C; Barro C; Hermouet S; Praloran V
Haematologica; 2004 Oct; 89(10):1194-8. PubMed ID: 15477203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
